TUCOWS INC /PA/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TUCOWS INC /PA/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $362.28M | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $339.34M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $321.14M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $304.34M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $311.20M | Jun 6, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $329.42M | Mar 6, 2018 |
| FY2017 | Dec 31, 2016 | $189.82M | Mar 6, 2018 |
| FY2017 | Dec 31, 2015 | $171.69M | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | $146.51M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $129.93M | Mar 9, 2016 |
| FY2014 | Dec 31, 2012 | $114.73M | Mar 11, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.95M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $83.03M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $66.67M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $78.25M | Mar 13, 2025 |
| FY2021 | Dec 31, 2021 | $24.58M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $18.02M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $18.24M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $17.45M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $17.43M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $19.94M | Mar 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.82M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($109.86M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($96.20M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($27.57M) | Mar 13, 2025 |
| FY2021 | Dec 31, 2021 | ($1.97M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $1.38M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $1.81M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $2.15M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $2.07M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $716.0K | Mar 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.48M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($65.01M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($63.65M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($31.66M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($7.77M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $6.92M | Jun 6, 2023 |
| FY2021 | Dec 31, 2019 | $29.34M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $29.32M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $27.08M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $25.05M | Mar 5, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.81M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $18.63M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $19.22M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $14.19M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $14.31M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $12.43M | Jun 6, 2023 |
| FY2021 | Dec 31, 2019 | $9.72M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $8.75M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $7.26M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $4.50M | Mar 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.76M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($19.75M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($4.77M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $19.88M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $29.64M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $36.08M | Jun 6, 2023 |
| FY2021 | Dec 31, 2019 | $40.38M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $37.21M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $31.90M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $22.51M | Mar 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.11M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $56.46M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $92.06M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $136.71M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $73.18M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $44.44M | Jun 6, 2023 |
| FY2021 | Dec 31, 2019 | $44.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $27.92M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $12.94M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $7.92M | Mar 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $730.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $758.80M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $798.43M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $664.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $539.60M | Jun 6, 2023 |
| FY2021 | Dec 31, 2020 | $451.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $425.92M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $339.58M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $350.65M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $154.41M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($164.20M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($95.30M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $9.88M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $96.66M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $115.09M | Mar 13, 2025 |
| FY2023 | Dec 31, 2020 | $104.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2019 | $94.19M | Jun 6, 2023 |
| FY2021 | Dec 31, 2018 | $79.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $60.21M | Mar 3, 2021 |
| FY2019 | Dec 31, 2016 | $37.82M | Mar 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.41M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $130.41M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $130.41M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $130.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $130.41M | Jun 6, 2023 |
| FY2022 | Dec 31, 2020 | $116.30M | Jun 6, 2023 |
| FY2021 | Dec 31, 2019 | $109.82M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $90.05M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $90.05M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $21.01M | Mar 6, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($225.98M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($150.16M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($40.30M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $55.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $83.47M | Jun 6, 2023 |
| FY2021 | Dec 31, 2020 | $80.11M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $76.21M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $60.81M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $42.68M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $20.40M | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.76M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $56.90M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $92.69M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $23.50M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $9.11M | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | $8.31M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $20.39M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $12.64M | Mar 4, 2020 |
| FY2019 | Dec 31, 2017 | $18.05M | Mar 4, 2020 |
| FY2019 | Dec 31, 2016 | $15.11M | Mar 4, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.40M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $195.40M | Mar 13, 2025 |
| FY2023 | Dec 31, 2023 | $211.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $239.70M | Jun 6, 2023 |
| FY2021 | Dec 31, 2021 | $191.40M | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $122.40M | Mar 3, 2021 |
| FY2019 | Dec 31, 2019 | $114.40M | Mar 4, 2020 |
| FY2018 | Dec 31, 2018 | $65.16M | Mar 5, 2019 |
| FY2017 | Dec 31, 2017 | $77.75M | Mar 6, 2018 |
| FY2016 | Dec 31, 2016 | $10.73M | Mar 8, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (8) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 13, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | (8) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.11M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 11.01M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 10.90M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 10.82M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 10.75M | Jun 6, 2023 |
| FY2021 | Dec 31, 2020 | 10.61M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 10.59M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 10.63M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 10.58M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | 10.46M | Mar 6, 2018 |